Mesa Laboratories, Inc. (NASDAQ:MLAB) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a one year consensus price target of $175.00 for the company and are anticipating that the company will post $0.61 earnings per share for the current quarter, according to Zacks. Zacks has also given Mesa Laboratories an industry rank of 158 out of 265 based on the ratings given to its competitors.
A number of analysts have commented on MLAB shares. TheStreet upgraded shares of Mesa Laboratories from a “c+” rating to a “b” rating in a research note on Monday, November 6th. Zacks Investment Research upgraded shares of Mesa Laboratories from a “strong sell” rating to a “buy” rating and set a $167.00 price target for the company in a research note on Tuesday, October 3rd.
Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.04). The firm had revenue of $22.95 million during the quarter, compared to analyst estimates of $25.50 million. Mesa Laboratories had a net margin of 11.48% and a return on equity of 14.77%. equities research analysts expect that Mesa Laboratories will post 2.47 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Wednesday, February 28th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend is Tuesday, February 27th. Mesa Laboratories’s dividend payout ratio is presently 23.10%.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Capital Analysts LLC acquired a new stake in shares of Mesa Laboratories during the 3rd quarter worth about $128,000. SG Americas Securities LLC acquired a new stake in shares of Mesa Laboratories during the 3rd quarter worth about $131,000. Voya Investment Management LLC acquired a new stake in shares of Mesa Laboratories during the 2nd quarter worth about $221,000. Westfield Capital Management Co. LP acquired a new stake in shares of Mesa Laboratories during the 3rd quarter worth about $239,000. Finally, BT Investment Management Ltd acquired a new stake in shares of Mesa Laboratories during the 2nd quarter worth about $277,000. Institutional investors own 69.79% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Mesa Laboratories, Inc. (MLAB) Given Average Recommendation of “Strong Buy” by Analysts” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://weekherald.com/2018/01/23/mesa-laboratories-inc-mlab-given-average-recommendation-of-strong-buy-by-analysts.html.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.